These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1007 related items for PubMed ID: 31505555

  • 1. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting.
    Lacoste JL, Hansen CL.
    Am J Health Syst Pharm; 2019 Sep 03; 76(18):1395-1402. PubMed ID: 31505555
    [Abstract] [Full Text] [Related]

  • 2. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
    Duerschmied D, Brachmann J, Darius H, Frey N, Katus HA, Rottbauer W, Schäfer A, Thiele H, Bode C, Zeymer U.
    Clin Res Cardiol; 2018 Jul 03; 107(7):533-538. PubMed ID: 29679144
    [Abstract] [Full Text] [Related]

  • 3. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M, Gibson CM, Chi G, Mehran R, AlKhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Fox KAA, Cohen M.
    JACC Cardiovasc Interv; 2018 Apr 09; 11(7):626-634. PubMed ID: 29550085
    [Abstract] [Full Text] [Related]

  • 4. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy.
    Desai A, Escamilla-Ocanas C, Dilip D, Saber H, Damani R.
    J Stroke Cerebrovasc Dis; 2021 Apr 09; 30(4):105654. PubMed ID: 33578352
    [Abstract] [Full Text] [Related]

  • 5. Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis.
    Ten Berg JM, de Veer A, Oldgren J, Steg PG, Zateyshchikov DA, Jansky P, Seung KB, Hohnloser SH, Lip GYH, Nordaby M, Kleine E, Bhatt DL, Cannon CP, RE-DUAL PCI Steering Committee and Investigators.
    JACC Cardiovasc Interv; 2019 Dec 09; 12(23):2331-2341. PubMed ID: 31806214
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Design and Rationale of the RE-DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etexilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting.
    Cannon CP, Gropper S, Bhatt DL, Ellis SG, Kimura T, Lip GY, Steg PG, Ten Berg JM, Manassie J, Kreuzer J, Blatchford J, Massaro JM, Brueckmann M, Ferreiros Ripoll E, Oldgren J, Hohnloser SH, RE-DUAL PCI Steering Committee and Investigators.
    Clin Cardiol; 2016 Oct 09; 39(10):555-564. PubMed ID: 27565018
    [Abstract] [Full Text] [Related]

  • 8. Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial.
    Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FWA, Wildgoose P, van Eickels M, Lip GYH, Cohen M, Fox KAA, Gibson CM.
    Circ Cardiovasc Interv; 2019 Nov 09; 12(11):e008160. PubMed ID: 31707805
    [Abstract] [Full Text] [Related]

  • 9. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention.
    Mishra A, Singh M, Acker WW, Kamboj S, Sporn D, Stapleton D, Kaluski E.
    J Cardiovasc Pharmacol; 2019 Aug 09; 74(2):82-90. PubMed ID: 31306367
    [Abstract] [Full Text] [Related]

  • 10. Triple therapy: A review of antithrombotic treatment for patients with atrial fibrillation undergoing percutaneous coronary intervention.
    Saito Y, Kobayashi Y.
    J Cardiol; 2019 Jan 09; 73(1):1-6. PubMed ID: 30293674
    [Abstract] [Full Text] [Related]

  • 11. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW, Cyr DD, Jones WS, Becker RC, Berkowitz SD, Washam JB, Breithardt G, Fox KA, Halperin JL, Hankey GJ, Singer DE, Piccini JP, Nessel CC, Mahaffey KW, Patel MR.
    JACC Cardiovasc Interv; 2016 Aug 22; 9(16):1694-702. PubMed ID: 27539689
    [Abstract] [Full Text] [Related]

  • 12. Concomitant Use of Antiplatelets and Anticoagulants in Patients with Coronary Heart Disease and Atrial Fibrillation: What Do Recent Clinical Trials Teach Us?
    Lam DH, Bell SM, Hira RS.
    Curr Atheroscler Rep; 2018 Jan 19; 20(1):4. PubMed ID: 29349596
    [Abstract] [Full Text] [Related]

  • 13. Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
    Xanthopoulou I, Dragona VM, Davlouros P, Tsioufis C, Iliodromitis E, Alexopoulos D, GRAPE-AF Investigators.
    Cardiovasc Drugs Ther; 2018 Apr 19; 32(2):191-196. PubMed ID: 29679301
    [Abstract] [Full Text] [Related]

  • 14. Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
    Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW.
    Am J Med; 2016 Jun 19; 129(6):592-599.e1. PubMed ID: 26797080
    [Abstract] [Full Text] [Related]

  • 15. Anticoagulation strategies in patients with atrial fibrillation after PCI or with ACS : The end of triple therapy?
    Fluschnik N, Becher PM, Schnabel R, Blankenberg S, Westermann D.
    Herz; 2018 Feb 19; 43(1):20-25. PubMed ID: 29188358
    [Abstract] [Full Text] [Related]

  • 16. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen.
    Kawakami S, Yasuda S, Ogawa H.
    J Cardiol; 2020 Jul 19; 76(1):35-43. PubMed ID: 32389534
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview.
    Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY.
    Thromb Haemost; 2014 Dec 19; 112(6):1080-7. PubMed ID: 25298351
    [Abstract] [Full Text] [Related]

  • 19. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention.
    Lamberts M, Gislason GH, Olesen JB, Kristensen SL, Schjerning Olsen AM, Mikkelsen A, Christensen CB, Lip GY, Køber L, Torp-Pedersen C, Hansen ML.
    J Am Coll Cardiol; 2013 Sep 10; 62(11):981-9. PubMed ID: 23747760
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.